Sissel Rodahl
Corporate Officer/Principal presso GENSIGHT BIOLOGICS S.A.
Profilo
Sissel Rodahl is currently the Senior Vice President-Commercial Operations at Gensight Biologics SA since 2022.
Prior to this, she worked as Vice President at Novartis Gene Therapies, Inc. from 2018 to 2022.
She completed her graduate degree from the University of Oslo and her undergraduate degree from Engineering College.
Posizioni attive di Sissel Rodahl
| Società | Posizione | Inizio |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Corporate Officer/Principal | 31/01/2022 |
Precedenti posizioni note di Sissel Rodahl
| Società | Posizione | Fine |
|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01/02/2022 |
Formazione di Sissel Rodahl
| University of Oslo | Graduate Degree |
| Engineering College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Aziende private | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Borsa valori
- Insiders
- Sissel Rodahl
